# Study to Evaluate the Safety and Efficacy of Jaktinib in Adults With Alopecia Areata

> **NCT05051761** · PHASE3 · COMPLETED · sponsor: **Suzhou Zelgen Biopharmaceuticals Co.,Ltd** · enrollment: 425 (actual)

## Conditions studied

- Alopecia Areata

## Interventions

- **DRUG:** Jaktinib
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT05051761
- **Lead sponsor:** Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-09-04
- **Primary completion:** 2023-12-27
- **Final completion:** 2023-12-27
- **Target enrollment:** 425 (ACTUAL)
- **Last updated:** 2025-03-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05051761

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05051761, "Study to Evaluate the Safety and Efficacy of Jaktinib in Adults With Alopecia Areata". Retrieved via AI Analytics 2026-06-29 from https://api.ai-analytics.org/clinical/NCT05051761. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*